Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

Comprehensive cardiac phenotyping in large animals: comparison of pressure-volume analysis and cardiac magnetic resonance imaging in pig post-myocardial infarction systolic heart failure.

Raake PWJ, Barthelmes J, Krautz B, Buss S, Huditz R, Schlegel P, Weber C, Stangassinger M, Haberkorn U, Katus HA, Most P, Pleger ST.

Int J Cardiovasc Imaging. 2019 Sep;35(9):1691-1699. doi: 10.1007/s10554-019-01610-z. Epub 2019 May 5.

PMID:
31056718
2.

Effects of MitraClip on cognitive and psychological function in heart failure patients: the sicker the better.

Terhoeven V, Nikendei C, Cranz A, Weisbrod M, Geis N, Raake PW, Katus HA, Herzog W, Friederich HC, Schultz JH, Pleger ST.

Eur J Med Res. 2019 Feb 22;24(1):14. doi: 10.1186/s40001-019-0371-z.

3.

Temporary oral anticoagulation after MitraClip - a strategy to lower the incidence of post-procedural stroke?

Geis N, Raake P, Kiriakou C, Mereles D, Frankenstein L, Abu-Sharar H, Chorianopoulos E, Katus HA, Bekeredjian R, Pleger ST.

Acta Cardiol. 2019 Jan 16:1-7. doi: 10.1080/00015385.2018.1550886. [Epub ahead of print]

PMID:
30650019
4.

Transient elevation of high-sensitive troponin T after Cardioband implantation.

Kreusser MM, Pleger ST, Abu Sharar H, Geis NA, Bekeredjian R, Katus HA, Raake PW.

Herz. 2019 Sep;44(6):546-552. doi: 10.1007/s00059-018-4754-7. Epub 2018 Sep 25.

PMID:
30255306
5.

Invasive hemodynamics and cardiac biomarkers to predict outcomes after percutaneous edge-to-edge mitral valve repair in patients with severe heart failure.

Kreusser MM, Geis NA, Berlin N, Greiner S, Pleger ST, Bekeredjian R, Katus HA, Raake PW.

Clin Res Cardiol. 2019 Apr;108(4):375-387. doi: 10.1007/s00392-018-1365-5. Epub 2018 Sep 6.

PMID:
30191296
6.

Haemodynamic effects of percutaneous mitral valve edge-to-edge repair in patients with end-stage heart failure awaiting heart transplantation.

Geis NA, Pleger ST, Bekeredjian R, Chorianopoulos E, Kreusser MM, Frankenstein L, Ruhparwar A, Katus HA, Raake PWJ.

ESC Heart Fail. 2018 Oct;5(5):892-901. doi: 10.1002/ehf2.12313. Epub 2018 Jul 30.

7.

The need for dedicated advanced heart failure units to optimize heart failure care: impact of optimized advanced heart failure unit care on heart transplant outcome in high-risk patients.

Kreusser MM, Tschierschke R, Beckendorf J, Baxmann T, Frankenstein L, Dösch AO, Schultz JH, Giannitsis E, Pleger ST, Ruhparwar A, Karck M, Katus HA, Raake PW.

ESC Heart Fail. 2018 Dec;5(6):1108-1117. doi: 10.1002/ehf2.12314. Epub 2018 Jul 9.

8.

Percutaneous repair of mitral valve regurgitation in patients with severe heart failure: comparison with optimal medical treatment.

Geis N, Raake P, Lewening M, Mereles D, Chorianopoulos E, Frankenstein L, Katus HA, Bekeredjian R, Pleger ST.

Acta Cardiol. 2018 Aug;73(4):378-386. doi: 10.1080/00015385.2017.1401275. Epub 2017 Nov 21.

PMID:
29161956
9.

Percutaneous repair of severe mitral valve regurgitation secondary to chordae rupture in octogenarians using MitraClip.

Geis N, Raake P, Mereles D, Chorianopoulos E, Szabo G, Katus HA, Bekeredjian R, Pleger ST.

J Interv Cardiol. 2018 Feb;31(1):76-82. doi: 10.1111/joic.12455. Epub 2017 Oct 12.

PMID:
29027267
10.

Feasibility and safety of vitamin K antagonist monotherapy in atrial fibrillation patients undergoing transcatheter aortic valve implantation.

Geis NA, Kiriakou C, Chorianopoulos E, Pleger ST, Katus HA, Bekeredjian R.

EuroIntervention. 2017 Apr 20;12(17):2058-2066. doi: 10.4244/EIJ-D-15-00259.

11.

The Effects of Mitral Valve Repair on Memory Performance, Executive Function, and Psychological Measures in Patients With Heart Failure.

Nikendei C, Schäfer H, Weisbrod M, Huber J, Geis N, Katus HA, Bekeredjian R, Herzog W, Pleger ST, Schultz JH.

Psychosom Med. 2016 May;78(4):432-42. doi: 10.1097/PSY.0000000000000284.

PMID:
26705072
12.

S100A1 DNA-based Inotropic Therapy Protects Against Proarrhythmogenic Ryanodine Receptor 2 Dysfunction.

Ritterhoff J, Völkers M, Seitz A, Spaich K, Gao E, Peppel K, Pleger ST, Zimmermann WH, Friedrich O, Fink RHA, Koch WJ, Katus HA, Most P.

Mol Ther. 2015 Aug;23(8):1320-1330. doi: 10.1038/mt.2015.93. Epub 2015 May 25.

13.

The extent of aortic annulus calcification is a predictor of postprocedural eccentricity and paravalvular regurgitation: a pre- and postinterventional cardiac computed tomography angiography study.

Bekeredjian R, Bodingbauer D, Hofmann NP, Greiner S, Schuetz M, Geis NA, Kauczor HU, Bryant M, Chorianopoulos E, Pleger ST, Mereles D, Katus HA, Korosoglou G.

J Invasive Cardiol. 2015 Mar;27(3):172-80.

14.

Using the GORE® Septal Occluder (GSO) in challenging patent foramen ovale (PFO) anatomies.

Geis NA, Pleger ST, Katus HA, Hardt SE.

J Interv Cardiol. 2015 Apr;28(2):190-7. doi: 10.1111/joic.12181. Epub 2015 Mar 2.

PMID:
25728716
15.

First experience with the new generation Edwards Sapien 3 aortic bioprosthesis: procedural results and short term outcome.

Murray MI, Geis N, Pleger ST, Kallenbach K, Katus HA, Bekeredjian R, Chorianopoulos E.

J Interv Cardiol. 2015 Feb;28(1):109-16. doi: 10.1111/joic.12182.

PMID:
25689554
16.

Feasibility of sheathless transfemoral aortic valve implantation in patients with small access vessel diameters.

Geis NA, Chorianopoulos E, Kallenbach K, André F, Pleger ST, Karck M, Katus HA, Bekeredjian R.

Clin Res Cardiol. 2014 Oct;103(10):775-80. doi: 10.1007/s00392-014-0713-3. Epub 2014 Apr 21.

PMID:
24748131
17.

Feasibility and clinical benefit of a suture-mediated closure device for femoral vein access after percutaneous edge-to-edge mitral valve repair.

Geis NA, Pleger ST, Chorianopoulos E, Müller OJ, Katus HA, Bekeredjian R.

EuroIntervention. 2015 Mar;10(11):1346-53. doi: 10.4244/EIJV10I11A231.

18.

Procedural results with the self-expanding 31 mm CoreValve aortic bioprosthesis in patients with large annuli.

Murray MI, Geis N, Pleger ST, Katus HA, Bekeredjian R, Chorianopoulos E.

J Interv Cardiol. 2014 Apr;27(2):191-8. doi: 10.1111/joic.12090. Epub 2014 Jan 16.

PMID:
24433399
19.

Cardiac calcium handling on trial: targeting the failing cardiomyocyte signalosome.

Pleger ST, Raake P, Katus HA, Most P.

Circ Res. 2014 Jan 3;114(1):12-4. doi: 10.1161/CIRCRESAHA.113.302748. No abstract available.

PMID:
24385502
20.

Therapeutic safety of high myocardial expression levels of the molecular inotrope S100A1 in a preclinical heart failure model.

Weber C, Neacsu I, Krautz B, Schlegel P, Sauer S, Raake P, Ritterhoff J, Jungmann A, Remppis AB, Stangassinger M, Koch WJ, Katus HA, Müller OJ, Most P, Pleger ST.

Gene Ther. 2014 Feb;21(2):131-8. doi: 10.1038/gt.2013.63. Epub 2013 Dec 5.

21.

Preserved prognostic value of preinterventional troponin T levels despite successful TAVI in patients with severe aortic stenosis.

Chorianopoulos E, Krumsdorf U, Geis N, Pleger ST, Giannitsis E, Katus HA, Bekeredjian R.

Clin Res Cardiol. 2014 Jan;103(1):65-72. doi: 10.1007/s00392-013-0624-8. Epub 2013 Oct 6.

PMID:
24096554
22.

Heart failure gene therapy: the path to clinical practice.

Pleger ST, Brinks H, Ritterhoff J, Raake P, Koch WJ, Katus HA, Most P.

Circ Res. 2013 Aug 30;113(6):792-809. doi: 10.1161/CIRCRESAHA.113.300269. Review.

PMID:
23989720
23.

One year clinical efficacy and reverse cardiac remodelling in patients with severe mitral regurgitation and reduced ejection fraction after MitraClip implantation.

Pleger ST, Schulz-Schönhagen M, Geis N, Mereles D, Chorianopoulos E, Antaredja M, Lewening M, Katus HA, Bekeredjian R.

Eur J Heart Fail. 2013 Aug;15(8):919-27. doi: 10.1093/eurjhf/hft046. Epub 2013 Mar 19.

24.

[Severe mitral valve regurgitation in terminal heart failure: news beyond guidelines].

Pleger ST, Katus HA, Bekeredjian R.

Dtsch Med Wochenschr. 2013 Mar;138(12):600-2. doi: 10.1055/s-0032-1333015. Epub 2013 Mar 12. Review. German. No abstract available.

PMID:
23483423
25.

Percutaneous edge-to-edge repair of mitral regurgitation as a bail-out strategy in critically ill patients.

Pleger ST, Chorianopoulos E, Krumsdorf U, Katus HA, Bekeredjian R.

J Invasive Cardiol. 2013 Feb;25(2):69-72.

26.

[High-risk patients with aortic valve stenosis. Interventional therapy].

Bekeredjian R, Pleger ST, Chorianopoulos E.

Herz. 2013 Mar;38(2):118-25. doi: 10.1007/s00059-012-3744-4. German.

PMID:
23324914
27.

S100A1 gene therapy in small and large animals.

Most P, Raake P, Weber C, Katus HA, Pleger ST.

Methods Mol Biol. 2013;963:407-20. doi: 10.1007/978-1-62703-230-8_25.

PMID:
23296625
28.

S100A1 deficiency impairs postischemic angiogenesis via compromised proangiogenic endothelial cell function and nitric oxide synthase regulation.

Most P, Lerchenmüller C, Rengo G, Mahlmann A, Ritterhoff J, Rohde D, Goodman C, Busch CJ, Laube F, Heissenberg J, Pleger ST, Weiss N, Katus HA, Koch WJ, Peppel K.

Circ Res. 2013 Jan 4;112(1):66-78. doi: 10.1161/CIRCRESAHA.112.275156. Epub 2012 Oct 9.

29.

C-reactive protein kinetics and its prognostic value after transfemoral aortic valve implantation.

Krumsdorf U, Chorianopoulos E, Pleger ST, Kallenbach K, Karck M, Katus HA, Bekeredjian R.

J Invasive Cardiol. 2012 Jun;24(6):282-6.

PMID:
22684383
30.

Improved procedural results after CoreValve implantation with the new AccuTrak delivery system.

Chorianopoulos E, Krumsdorf U, Pleger ST, Katus HA, Bekeredjian R.

J Interv Cardiol. 2012 Apr;25(2):174-9. doi: 10.1111/j.1540-8183.2011.00695.x.

PMID:
22487134
31.

Targeting GRK2 by gene therapy for heart failure: benefits above β-blockade.

Reinkober J, Tscheschner H, Pleger ST, Most P, Katus HA, Koch WJ, Raake PW.

Gene Ther. 2012 Jun;19(6):686-93. doi: 10.1038/gt.2012.9. Epub 2012 Feb 16. Review.

PMID:
22336718
32.

Percutaneous and surgical treatment of mitral valve regurgitation.

Seeburger J, Katus HA, Pleger ST, Krumsdorf U, Mohr FW, Bekeredjian R.

Dtsch Arztebl Int. 2011 Dec;108(48):816-21. doi: 10.3238/arztebl.2011.0816. Epub 2011 Dec 2. Review.

33.

Incidence of late occurring bradyarrhythmias after TAVI with the self-expanding CoreValve(®) aortic bioprosthesis.

Chorianopoulos E, Krumsdorf U, Pleger ST, Katus HA, Bekeredjian R.

Clin Res Cardiol. 2012 May;101(5):349-55. doi: 10.1007/s00392-011-0398-9. Epub 2011 Dec 18.

PMID:
22179559
34.

Acute safety and 30-day outcome after percutaneous edge-to-edge repair of mitral regurgitation in very high-risk patients.

Pleger ST, Mereles D, Schulz-Schönhagen M, Krumsdorf U, Chorianopoulos E, Rottbauer W, Katus HA, Bekeredjian R.

Am J Cardiol. 2011 Nov 15;108(10):1478-82. doi: 10.1016/j.amjcard.2011.06.069. Epub 2011 Sep 3.

PMID:
21890084
35.

S100A1 genetically targeted therapy reverses dysfunction of human failing cardiomyocytes.

Brinks H, Rohde D, Voelkers M, Qiu G, Pleger ST, Herzog N, Rabinowitz J, Ruhparwar A, Silvestry S, Lerchenmüller C, Mather PJ, Eckhart AD, Katus HA, Carrel T, Koch WJ, Most P.

J Am Coll Cardiol. 2011 Aug 23;58(9):966-73. doi: 10.1016/j.jacc.2011.03.054.

36.

Cardiac AAV9-S100A1 gene therapy rescues post-ischemic heart failure in a preclinical large animal model.

Pleger ST, Shan C, Ksienzyk J, Bekeredjian R, Boekstegers P, Hinkel R, Schinkel S, Leuchs B, Ludwig J, Qiu G, Weber C, Raake P, Koch WJ, Katus HA, Müller OJ, Most P.

Sci Transl Med. 2011 Jul 20;3(92):92ra64. doi: 10.1126/scitranslmed.3002097.

37.

HMGB1: the missing link between diabetes mellitus and heart failure.

Volz HC, Seidel C, Laohachewin D, Kaya Z, Müller OJ, Pleger ST, Lasitschka F, Bianchi ME, Remppis A, Bierhaus A, Katus HA, Andrassy M.

Basic Res Cardiol. 2010 Nov;105(6):805-20. doi: 10.1007/s00395-010-0114-3. Epub 2010 Aug 12.

PMID:
20703492
38.

Long-term survival of cancer patients compared to heart failure and stroke: a systematic review.

Askoxylakis V, Thieke C, Pleger ST, Most P, Tanner J, Lindel K, Katus HA, Debus J, Bischof M.

BMC Cancer. 2010 Mar 22;10:105. doi: 10.1186/1471-2407-10-105. Review.

39.

S100A1 in cardiovascular health and disease: closing the gap between basic science and clinical therapy.

Kraus C, Rohde D, Weidenhammer C, Qiu G, Pleger ST, Voelkers M, Boerries M, Remppis A, Katus HA, Most P.

J Mol Cell Cardiol. 2009 Oct;47(4):445-55. doi: 10.1016/j.yjmcc.2009.06.003. Epub 2009 Jun 16. Review.

40.

High-mobility group box-1 in ischemia-reperfusion injury of the heart.

Andrassy M, Volz HC, Igwe JC, Funke B, Eichberger SN, Kaya Z, Buss S, Autschbach F, Pleger ST, Lukic IK, Bea F, Hardt SE, Humpert PM, Bianchi ME, Mairbäurl H, Nawroth PP, Remppis A, Katus HA, Bierhaus A.

Circulation. 2008 Jun 24;117(25):3216-26. doi: 10.1161/CIRCULATIONAHA.108.769331.

PMID:
18574060
41.

Endothelial S100A1 modulates vascular function via nitric oxide.

Pleger ST, Harris DM, Shan C, Vinge LE, Chuprun JK, Berzins B, Pleger W, Druckman C, Völkers M, Heierhorst J, Øie E, Remppis A, Katus HA, Scalia R, Eckhart AD, Koch WJ, Most P.

Circ Res. 2008 Apr 11;102(7):786-94. doi: 10.1161/CIRCRESAHA.108.172031. Epub 2008 Feb 21.

PMID:
18292599
42.

Recent findings into the potential of gene therapy to reverse heart failure.

Pleger ST, Most P, Koch WJ.

Expert Opin Biol Ther. 2007 Dec;7(12):1781-4.

PMID:
18034643
43.

Targeting myocardial beta-adrenergic receptor signaling and calcium cycling for heart failure gene therapy.

Pleger ST, Boucher M, Most P, Koch WJ.

J Card Fail. 2007 Jun;13(5):401-14. Review.

PMID:
17602988
44.

S100 proteins: a missing piece in the puzzle of heart failure?

Pleger ST, Most P, Katus HA.

Cardiovasc Res. 2007 Jul 1;75(1):1-2. Epub 2007 May 10. No abstract available.

PMID:
17531210
45.

Stable myocardial-specific AAV6-S100A1 gene therapy results in chronic functional heart failure rescue.

Pleger ST, Most P, Boucher M, Soltys S, Chuprun JK, Pleger W, Gao E, Dasgupta A, Rengo G, Remppis A, Katus HA, Eckhart AD, Rabinowitz JE, Koch WJ.

Circulation. 2007 May 15;115(19):2506-15. Epub 2007 Apr 30.

PMID:
17470693
46.

S100A1: a novel inotropic regulator of cardiac performance. Transition from molecular physiology to pathophysiological relevance.

Most P, Remppis A, Pleger ST, Katus HA, Koch WJ.

Am J Physiol Regul Integr Comp Physiol. 2007 Aug;293(2):R568-77. Epub 2007 Apr 25. Review.

47.

S100A1 gene transfer in myocardium.

Pleger ST, Most P, Heidt B, Voelkers M, Hata JA, Katus HA, Remppis A, Koch WJ.

Eur J Med Res. 2006 Oct 27;11(10):418-22.

PMID:
17107875
48.

Cardiac S100A1 protein levels determine contractile performance and propensity toward heart failure after myocardial infarction.

Most P, Seifert H, Gao E, Funakoshi H, Völkers M, Heierhorst J, Remppis A, Pleger ST, DeGeorge BR Jr, Eckhart AD, Feldman AM, Koch WJ.

Circulation. 2006 Sep 19;114(12):1258-68. Epub 2006 Sep 4.

PMID:
16952982
49.

Pharmacological- and gene therapy-based inhibition of protein kinase Calpha/beta enhances cardiac contractility and attenuates heart failure.

Hambleton M, Hahn H, Pleger ST, Kuhn MC, Klevitsky R, Carr AN, Kimball TF, Hewett TE, Dorn GW 2nd, Koch WJ, Molkentin JD.

Circulation. 2006 Aug 8;114(6):574-82. Epub 2006 Jul 31.

50.

Supplemental Content

Loading ...
Support Center